On February 22, 2022 RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, reported enrollment of its first patient at one of its newest clinical sites, Columbia University New York-Presbyterian Hospital Irving Medical Center ("Columbia University"), in its ongoing TIGeR-PaC Phase 3 clinical trial (Press release, Renovorx, FEB 22, 2022, View Source [SID1234608834]). The study is evaluating the Company’s therapy platform RenovoTAMP (RenovoRx Trans-Arterial Micro-Perfusion), as a potential treatment option for locally advanced pancreatic cancer ("LAPC") that may extend life while improving quality of life by reducing the often debilitating side-effects associated with systemic chemotherapy delivered intra-venously.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Columbia University is the most recent trial site to join the Phase 3 study which continues enrolling patients at participating clinical sites across the U.S.
"Cancer of the pancreas is aggressive and difficult to detect and treat," said Principal Investigator Susan Bates, M.D., Professor of Medicine at Columbia University Irving Medical Center.
Dr. Bates added, "Treatment options have been limited to systemic chemotherapy for most patients. Local perfusion allows us to deliver much higher concentrations of an effective agent to the tumor. In the TIGeR-PaC trial, the tumor is temporarily isolated and saturated with gemcitabine, a well validated chemotherapeutic agent. In comparison to systemic chemotherapy treatment, RenovoRx has shown in its Phase 1/2 clinical trials that its therapy platform delivers a higher concentration of chemotherapy directly to the tumor with reduced patient side effects. This trial will offer a proof-of-principle that could establish direct delivery of chemotherapy as a strategy for treating pancreatic cancer in various settings."
Dr. Ramtin Agah, RenovoRx’s Founder and Chief Medical Officer, commented, "Dr. Bates and her Columbia University team share our deep commitment to helping pancreatic cancer patients. Enrolling our first patient at this renowned institution is an important milestone for the TIGeR-PaC clinical trial. This also gives more LAPC patients in New York, New Jersey and Connecticut an opportunity to participate in this study."
To learn more about RenovoRx’s ongoing clinical trials, please visit the Clinical Trials page of our website.
About the Phase 3 TIGeR-PaC Clinical Trial
The TIGeR-PaC clinical trial is a randomized multi-center study using the RenovoTAMP platform to evaluate RenovoRx’s first product candidate, RenovoGem to treat unresectable LAPC through the intra-arterial delivery of gemcitabine. TIGeR-PaC is currently enrolling locally advanced, unresectable pancreatic cancer patients. To learn more about the study and the participating clinical trial sites, visit View Source